|Bid||41.03 x 800|
|Ask||73.17 x 800|
|Day's Range||56.21 - 58.07|
|52 Week Range||41.82 - 88.00|
|Beta (5Y Monthly)||0.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||72.17|
Subscribe to Yahoo Finance Plus to view Fair Value for LIVN
LONDON, February 02, 2023--LivaNova launched SenTiva DUO™, an implantable pulse generator with a dual-pin header to provide VNS Therapy™ for drug-resistant epilepsy treatment.
The U.S. Food and Drug Administration on Friday classified the recall of LivaNova's device that controls a blood-pumping system at its most serious type, citing that their use could cause serious injuries or death. The medical device company recalled 589 units of the LifeSPARC system's controller, through the period of Dec. 19, 2019 to Nov. 17, 2022, for a software update to address a previously known malfunction. The controller's software malfunction may trigger the device to enter critical failure mode causing the pump to stop for an extended time period, the FDA said, which may lead to serious injury or death of the patient.
LONDON, January 18, 2023--LivaNova PLC will host a conference call to discuss its fourth-quarter and full-year 2022 results on Feb. 22, 2023 at 1 p.m. London time (8 a.m. ET).